Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23481
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRobinson, Danielle H-
dc.contributor.authorHughes, Charlotte F M-
dc.contributor.authorGrigg, Andrew P-
dc.date2020-05-30-
dc.date.accessioned2020-06-10T00:47:13Z-
dc.date.available2020-06-10T00:47:13Z-
dc.date.issued2020-10-
dc.identifier.citationLeukemia & lymphoma 2020; 61(10): 2448-2452-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23481-
dc.description.abstractCyclosporin is an immunosuppressive agent in allogeneic hematopoietic stem cell transplantation and its metabolism is strongly affected by concomitant drugs, including posaconazole which is now extensively used as anti-fungal prophylaxis post-allograft. We undertook a retrospective audit of 29 patients undergoing their first allograft who were receiving posaconazole at the time of transition from intravenous to oral cyclosporin. This group had a median initial oral cyclosporin dose of 2.58 mg/kg bd (range 1.75-3.95) and high incidence of cyclosporin-related toxicity was noted, requiring significant dose reductions such that by day 60 the media dose was 1.60 mg/kg bd (range 0.86-3.33). We subsequently amended our dosing protocol and analyzed a further 20 patients specifying an initial oral cyclosporin dose of 2.25 mg/kg bd and found this had little impact on toxicity or requirement for dose reductions. Starting doses of no greater than 2 mg/kg bd appear optimal to prevent toxicity in allograft recipients receiving concomitant posaconazole.-
dc.language.isoeng-
dc.subjectTransplantation-
dc.subjectcyclosporin-
dc.subjectdrug toxicity-
dc.subjectposaconazole-
dc.titleOptimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.-
dc.typeJournal Article-
dc.identifier.journaltitleLeukemia & lymphoma-
dc.identifier.affiliationDepartment of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1080/10428194.2020.1768381-
dc.identifier.orcid0000-0001-9809-6757en
dc.identifier.orcid0000-0003-0384-704Xen
dc.identifier.pubmedid32476517-
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.